Nuformix Secures U.S. Orphan Drug Designation for IPF Therapy Candidate NXP002

Nuformix (LSE:NFX) has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for tranilast lystate, the inhaled active compound used in its NXP002 programme for idiopathic pulmonary fibrosis (IPF), a rare and often fatal lung disease. The designation follows a similar orphan status previously awarded in Europe and provides several development incentives, including potential tax credits, reduced regulatory fees and the possibility of market exclusivity. Nuformix said the recognition could strengthen its position in ongoing licensing discussions and increase the strategic value of the NXP002 programme for potential partners.

With orphan designation now secured in both the United States and Europe, Nuformix is further establishing its presence in the specialised fibrosis treatment space. The regulatory support could help accelerate progress toward future clinical and commercial milestones. The company said the achievement also demonstrates the potential of its drug repurposing approach to generate regulatory assets that may attract partnerships and support longer-term value creation, although the programme remains at a preclinical stage.

The company’s broader outlook remains constrained by weak financial performance, including the absence of recent revenue, continuing losses and sustained negative free cash flow, though it operates without debt. Technical indicators also suggest downside pressure, with the share price trading below key short- and medium-term averages and a negative MACD signal. Valuation metrics are similarly limited by negative earnings and the lack of dividend support.

More about Nuformix Plc

Nuformix plc is a UK-listed pharmaceutical development company focused on treating unmet medical needs in fibrosis and oncology through drug repurposing. The company specialises in identifying, developing and patenting improved forms of existing drugs with enhanced physical properties, creating differentiated products with new commercial opportunities and early-stage licensing potential from its pipeline of preclinical assets.